Limits...
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.

Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ - Eur. Respir. J. (2015)

Bottom Line: The risk of morbidity/mortality and PAH-related death/hospitalisation was determined using Cox regression.The risk of morbidity/mortality (Kaplan-Meier estimates at month 12: 54.4% versus 26.7%; p=0.006) and PAH-related death/hospitalisation (Kaplan-Meier estimates at month 12: 47.3% versus 19.9%; p=0.006) were significantly higher for incident versus prevalent patients receiving placebo, respectively.There was no significant difference in the risk of all-cause death between incident and prevalent cohorts (p=0.587).Macitentan 10 mg significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation versus placebo in incident and prevalent cohorts.Incident patients had a higher risk for PAH progression compared with prevalent patients but not a higher risk of death.

View Article: PubMed Central - PubMed

Affiliation: Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France gerald.simonneau@bct.aphp.fr.

No MeSH data available.


Related in: MedlinePlus

Effect of macitentan 10 mg on pulmonary arterial hypertension-related death or hospitalisation in treatment-naïve incident and prevalent cohorts.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664609&req=5

Figure 3: Effect of macitentan 10 mg on pulmonary arterial hypertension-related death or hospitalisation in treatment-naïve incident and prevalent cohorts.

Mentions: The total number of PAH-related death or hospitalisation events experienced by patients in the incident and prevalent cohorts is shown by treatment group in table 2. Among the placebo patients, a greater proportion of incident patients experienced a PAH-related death or hospitalisation event compared with prevalent patients; this end-point was mainly driven by hospitalisation for PAH (table 2). Kaplan–Meier estimates of PAH-related death or hospitalisation at month 12 were 47.3% versus 19.9% for the incident and prevalent patients, respectively (figure 3). These estimates correspond to more than twice the risk of occurrence of an event throughout the entire treatment period, for incident versus prevalent patients (HR 2.47, 95% CI 1.27–4.83; log-rank p=0.006). After adjustment for baseline variables that differed at the 20% level between incident and prevalent placebo groups (geographical region, mRAP and WHO FC) and aetiology, the HR was 1.98 (95% CI 0.89–4.43) (table S1).FIGURE 3


Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.

Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ - Eur. Respir. J. (2015)

Effect of macitentan 10 mg on pulmonary arterial hypertension-related death or hospitalisation in treatment-naïve incident and prevalent cohorts.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664609&req=5

Figure 3: Effect of macitentan 10 mg on pulmonary arterial hypertension-related death or hospitalisation in treatment-naïve incident and prevalent cohorts.
Mentions: The total number of PAH-related death or hospitalisation events experienced by patients in the incident and prevalent cohorts is shown by treatment group in table 2. Among the placebo patients, a greater proportion of incident patients experienced a PAH-related death or hospitalisation event compared with prevalent patients; this end-point was mainly driven by hospitalisation for PAH (table 2). Kaplan–Meier estimates of PAH-related death or hospitalisation at month 12 were 47.3% versus 19.9% for the incident and prevalent patients, respectively (figure 3). These estimates correspond to more than twice the risk of occurrence of an event throughout the entire treatment period, for incident versus prevalent patients (HR 2.47, 95% CI 1.27–4.83; log-rank p=0.006). After adjustment for baseline variables that differed at the 20% level between incident and prevalent placebo groups (geographical region, mRAP and WHO FC) and aetiology, the HR was 1.98 (95% CI 0.89–4.43) (table S1).FIGURE 3

Bottom Line: The risk of morbidity/mortality and PAH-related death/hospitalisation was determined using Cox regression.The risk of morbidity/mortality (Kaplan-Meier estimates at month 12: 54.4% versus 26.7%; p=0.006) and PAH-related death/hospitalisation (Kaplan-Meier estimates at month 12: 47.3% versus 19.9%; p=0.006) were significantly higher for incident versus prevalent patients receiving placebo, respectively.There was no significant difference in the risk of all-cause death between incident and prevalent cohorts (p=0.587).Macitentan 10 mg significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation versus placebo in incident and prevalent cohorts.Incident patients had a higher risk for PAH progression compared with prevalent patients but not a higher risk of death.

View Article: PubMed Central - PubMed

Affiliation: Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France gerald.simonneau@bct.aphp.fr.

No MeSH data available.


Related in: MedlinePlus